NCT06647134 A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
| NCT ID | NCT06647134 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-09-11 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2024-09-11 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Eligibility Criteria
Inclusion Criteria The criteria are: * Patients aged 18 years and above * English (conversational level) speaking, with the ability to give informed consent * Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy Exclusion Criteria * Acutely life-threatening or worsening cancer * Hearing impairment functionally limiting participation in verbal interview
Contact & Investigator
Y. Jeff Li, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06647134 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06647134 currently recruiting?
Yes, NCT06647134 is actively recruiting participants. Contact the research team at yli61@mdanderson.org for enrollment information.
Where is the NCT06647134 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06647134 clinical trial?
NCT06647134 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Y. Jeff Li, MD at M.D. Anderson Cancer Center. The trial plans to enroll 20 participants.